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Abstract
Background and Aim: Individuals with Lynch syndrome (LS) are at increased risk of LS-
related cancers including colorectal cancer (CRC). CRC tumor screening for mismatch re-
pair (MMR) deﬁciency is recommended in Australia to identify LS, although its cost-
effectiveness has not been assessed. We aim to determine the cost-effectiveness of screen-
ing individuals with CRC for LS at different age-at-diagnosis thresholds.
Methods: We developed a decision analysis model to estimate yield and costs of LS
screening. Age-speciﬁc probabilities of LS diagnosis were based on Australian data. Two
CRC tumor screening pathways were assessed (MMR immunohistochemistry followed
by MLH1 methylation (MLH1-Pathway) or BRAF V600E testing (BRAF-Pathway) if
MLH1 expression was lost) for four age-at-diagnosis thresholds—screening < 50, screen-
ing < 60, screening < 70, and universal screening.
Results: Per 1000 CRC cases, screening < 50 identiﬁed 5.2 LS cases and cost $A7041 per
case detected in the MLH1-Pathway. Screening < 60 increased detection by 1.5 cases for
an incremental cost of $A25 177 per additional case detected. Screening < 70 detected
1.6 additional cases at an incremental cost of $A40 278 per additional case detected. Com-
pared with screening < 70, universal screening detected no additional LS cases but cost
$A158 724 extra. The BRAF-Pathway identiﬁed the same number of LS cases for higher
costs.
Conclusions: The MLH1-Pathway is more cost-effective than BRAF-Pathway for all age-
at-diagnosis thresholds. MMR immunohistochemistry tumor screening in individuals diag-
nosed with CRC aged < 70 years resulted in higher LS case detection at a reasonable cost.
Further research into the yield of LS screening in CRC patients ≥ 70 years is needed to de-
termine if universal screening is justiﬁed.
Introduction
Colorectal cancer (CRC) is a leading cause of cancer incidence
and mortality in Australia.1 While diagnoses are predominantly
made in those at older ages, certain groups are at increased risk
of early-onset CRC, largely as a result of inherited genetic muta-
tions.2 Lynch syndrome (LS), an autosomal dominant condition,
is a well-known genetic syndrome that increases risk of early-
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onset CRC (average age at diagnosis is 42 years for men and
47 years for women3). Caused by a germline mutation in one of
the DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6,
or PMS2), LS is characterized by tumors that develop with high
levels of microsatellite instability (MSI) and loss of expression
of one or more of the MMR proteins, collectively referred to as tu-
mor MMR deﬁciency.
Lynch syndrome is estimated to cause 1–3% of all CRC cases4
with carriers experiencing accelerated carcinogenesis and an in-
creased lifetime risk for CRC (10–47% by age 70 years5–7 com-
pared with 4–5%8 in the general population) as well as
predisposing individuals to other cancers.9,10 A diagnosis of LS
aids clinical decision-making, including more extensive surgery
and highly intensive long-term surveillance, which impacts patient
outcomes.4 Furthermore, a diagnosis permits cascade testing of at-
risk family members to determine LS carrier status, thus enabling
the commencement of intensive surveillance, which has been
shown to lead to a reduction in LS-related cancer incidence and
mortality.11–15
Historically, LS testing has been guided using the Amsterdam or
revised Bethesda criteria, both of which rely on obtaining an accu-
rate family history12 but have limited sensitivity and speciﬁcity for
LS detection and are poorly implemented in routine clinical prac-
tice.4,16,17 More recently, screening for LS has begun with tumor
testing for MMR deﬁciency, prior to proceeding to germline
MMR gene testing.17–19 However, as MMR deﬁciency can also
be caused by sporadic somatic hypermethylation of the MLH1
gene promoter, tumors showing loss of MLH1/PMS2 protein
expression require further testing (with either somatic MLH1
methylation testing or BRAF V600E somatic mutation testing). If
LS is still suspected after these tumor tests, genetic testing is
offered in association with genetic counseling.
Within Australia, there is no national policy for LS screening;
however, the National Health and Medical Research Council re-
cently recommended universal screening,20 as a means of increas-
ing identiﬁcation of carriers and their at-risk relatives. While this
recommendation is in line with other juristrictions,4,21 no cost-
effectiveness analyses have been conducted in the Australian set-
ting and therefore the optimal screening strategy remains unclear.
We aimed to determine the cost-effectiveness of CRC tumor
screening to identify LS at different age-at-diagnosis thresholds
for two alternative tumor screening pathways using data from the
Australian setting.
Methods
Overview. We developed a decision analysis model to simulate
LS screening in individuals with CRC to estimate the annual yield
and costs associated with identifying LS this population. For tumors
exhibiting loss ofMLH1/PMS2 expression by MMR immunohisto-
chemistry (IHC), we tested two alternative pathways based on the
follow-up tumor test (MLH1 methylation test or a BRAF V600E
mutation test). The primary focus was to determine how yield and
cost would vary for each pathway by age-at-diagnosis and compare
the incremental differences within and between the pathways.
Data. Model parameters were based on two Australian research
studies, the Australasian Colorectal Cancer Family Registry and
the Melbourne Collaborative Cohort Study, which have been sys-
tematically characterized for LS. Detailed information about the
recruitment strategy and tumor testing for these studies has been
previously reported.18 In brief, the Australasian Colorectal Cancer
Family Registry recruited population-based incident CRC cases of
individuals aged 18–59 years (eligible cases n = 813) between
1997 and 2007. The Melbourne Collaborative Cohort Study is an
Australian cohort study of 41 513 Melbourne residents recruited
during 1990–1994 with age range at recruitment of 27–80 years.
Data from 826 CRC cases diagnosed from recruitment until
2010 and aged 41–86 years at diagnosis were used for this
analysis.
Colorectal cancer tumor samples from both studies were tested
for MMR protein expression using IHC. Tumors showing MMR
deﬁciency underwent germline testing to identify a MMR gene
mutation and conﬁrm LS diagnosis. For tumors demonstrating loss
of MLH1/PMS2 expression by IHC, testing for tumor MLH1 pro-
moter hypermethylation and BRAF V600E somatic mutation were
performed, and only those cases with no evidence of somatic
MLH1 methylation or BRAF wild-type underwent germline testing
of MLH1 gene.
Decision analysis model. Using TreeAge Pro 2016
(Williamstown, Massachusetts), we developed a decision analysis
model to simulate LS screening. For tumors exhibiting loss of
MLH1/PMS2 expression by MMR IHC, we assessed two screen-
ing pathways for identifying LS based on follow-up tumor testing.
In the ﬁrst model (MLH1-Pathway), IHC was followed by somatic
MLH1 methylation testing (Fig. 1), while in the second model
(BRAF-Pathway), IHC was followed by BRAF V600E mutation
testing (Fig. 2). For each pathway, we simulated 1000 CRC cases
and assumed 100% participation in tumor and genetic testing at all
stages. Once a diagnosis of CRC has been made, eligible individ-
uals entered the LS screening pathway and progressed based on
age-speciﬁc probabilities (Figs 1, 2). Costs are applied at appropri-
ate time points along the pathway, such as when a test is conducted
or when genetic counseling would be initiated.
Screening scenarios. For this analysis, we used empirical
data18 to assess four age-at-diagnosis scenarios: screening < 50,
screening< 60, screening< 70, and universal screening. In the ref-
erence scenario, screening < 50, screening was restricted to CRC
diagnoses occurring before the age of 50 years. Screening< 60 ex-
panded tumor screening to include those aged 50–59 years, and
screening < 70 is a further expansion to include cases aged 60–
69 years. The universal scenario included screening of all incident
CRC diagnoses regardless of age. The probability of meeting the
LS screening eligibility criteria for the age-restricted scenarios
was based on Australian CRC incidence data from 2008 to 2012.8
Cost assumptions. The cost of MMR IHC was provided by
The Royal College of Pathologists of Australasia Benchmarking in
Pathology Quality Assurance Program (St. Leonards, NSW)
(2013) results (Dr Tony Badrick, pers. comm.). For the MLH1
methylation testing, cost data were provided by PathWest Labora-
tory Medicine, Nedlands, the sole government pathology service
for Western Australia (Dr Benhur Amanuel, pers. comm.). The
Costs and outcomes of Lynch syndrome DR Cenin et al.
1738 Journal of Gastroenterology and Hepatology 33 (2018) 1737–1744
© 2018 The Authors Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology
and Hepatology Foundation and John Wiley & Sons Australia, Ltd
cost ofBRAFV600E testingwas taken fromMBSOnline22 (Table 1).
Germline testing costs were provided by the Department of Diagnos-
tic Genomics, PathWest Laboratory Medicine, Nedlands, the pri-
mary laboratory for genetic testing in Western Australia (Dr Karen
Carpenter, pers. comm.). The costs for genetic counseling were ob-
tained from primary sources at Genetic Services of Western
Australia (Subiaco, WA), including the Business Unit and genetic
counselors (Anne Hawkins and Cassandra Nichols, pers. comm.).
All costs are presented in 2016 Australian dollars, and as they
are incurred in a single year, no discounting is required.
Outcomes. For each screening pathway, our decision analysis
model estimated the annual yield and costs of identifying LS in the
four age-restricted scenarios per 1000 CRC cases.
Sensitivity analyses. To evaluate the robustness of our
model outcomes, we conducted a number if univariate analyses.
Firstly, we assessed the uncertainty of the diagnostic accuracy by
calculating the 95% conﬁdence intervals around the probability
of being diagnosed with LS after demonstrating MMR deﬁciency
using the Wilson conﬁdence interval. This provided lower and up-
per conﬁdence limits of yield and costs of LS screening in the
CRC population.
Furthermore, as no cases of LS were diagnosed in CRC patients
aged ≥ 70 years in our data set, we performed an analysis of the
MLH1-Pathway using age-speciﬁc probabilities derived from
Hampel et al.30 to assess the impact of identifying LS cases in this
age group. Unfortunately, similar data were not available from this
research to assess the BRAF-Pathway.
Finally, we reduced acceptance of genetic counseling to
92.5%23 and varied the acceptance of germline testing to 81%17
and 90%23 to assess the impact of these variables on yield and
costs of LS screening.
For all sensitivity analyses, we also explored the effect of vary-
ing costs parameters by assuming a 50% reduction and a twofold
Figure 1 MLH1-Pathway with age-speciﬁc probabilities of progressing through the Lynch syndrome (LS) screening pathway. †Probability of meeting
inclusion criteria in the age-restricted scenarios is based on the age distribution of colorectal cancer (CRC) incidence data from 2008 to 2012.8 ‡MMR
deﬁciency is determined by testing with IHC and is deﬁned as loss of MMR expression in one or more of the four MMR genes (MLH1, PMS2, MSH2,
and MSH6). §Progression through the pathway is based on probabilities derived from Buchanan et al.18 These probabilities differ slightly as we consid-
ered LS cases that did not show MMR deﬁciency with IHC to be missed cases (three cases in screening < 60 and screening < 70 and four cases in
universal). In addition, one LS case was excluded from the probabilities in our analysis because although the case showed PMS2 loss, genetic testing
identiﬁed an MLH1 mutation, and this could not be factored into the model. Using screening < 50 as the example, 7.6% of all CRC cases were eligible
for testing with IHC to determine MMR deﬁciency status and 13.5% were MMR deﬁcient. Of these, 52.8% had loss of MLH1/PMS2, 18.1% had loss
of MSH2/MSH6, 12.5% had loss of MSH6 only, and 16.7% had loss of PMS2 only. Of the tumors with of MHL1/PMS2, 92.1%were unmethylated and
went on for germline testing. LS was conﬁrmed in 66.7% of CRC cases demonstrating MLH1/PMS2 loss (excludingMLH1-methylated CRCs), 61.5%
of the cases demonstrating MSH2/MSH6 loss, 77.8% of the cases demonstrating MSH6 loss, and 66.7% of the cases demonstrating PMS2 only.
CRC, colorectal cancer; IHC, immunohistochemistry; LS, Lynch syndrome; MMR, mismatch repair; < 60, age-speciﬁc probabilities for CRC cases aged
under 60 years; 60–69, age-speciﬁc probabilities for CRC cases aged between 60 and 69 years; 70+, age-speciﬁc probabilities for CRC cases aged over
70 years.
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increase of all costs (Table 1 and tables in the Supporting Informa-
tion). This provided lower and upper bound cost estimates for each
age cohort in the analyses.
Results
MLH1-Pathway. By restricting testing to CRC cases diag-
nosed < 50 years, 76 (7.6%) of the 1000 CRC cases would be
tested with IHC, leading to the identiﬁcation of 5.2 LS cases. Total
costs for this pathway were $36 864 per 1000 CRC cases, equating
to $7041 per LS case diagnosed.
By expanding screening to include those aged between 50 and
59 years (screening < 60), an extra 142 individuals (totaling
21.8% of total CRC patient population) would be tested with
IHC to identify 1.5 additional LS cases (6.7 LS cases in total). This
would cost an additional $36 794 or $25 177 per additional LS
case diagnosed. Cost per case detected increased to $10 999.
With further expansion to also screen CRC cases aged between
60 and 69 years (screening < 70), an additional 255 individuals
(totaling 47.3% of total CRC patient population) would be tested
by IHC. This identiﬁed 1.6 additional LS cases (8.3 LS cases in to-
tal), annual program cost increased to $138 663, and the cost per
additional case detected was $40 278. Cost per case detected in-
creased to $16 685.
Based on our data, universal screening would not identify any
additional LS cases; however, annual program cost would increase
by $158 724 to $297 387 per 1000 CRC cases. Cost per LS case
detected increased to $35 784.
BRAF-Pathway. The BRAF-Pathway identiﬁed the same
number of LS cases as the MLH1-Pathway at higher costs
(Table 2). For example, screening < 50 identiﬁed 5.2 LS cases
per 1000 CRC cases and cost $36 462 for the MLH1-Pathway
and $37 177 in the BRAF-Pathway. Therefore, LS screening based
on IHC followed by BRAF V600E is more expensive than the
alternative, and the BRAF-Pathway is subsequently dominated in
terms of cost-effectiveness.
Figure 2 BRAF-Pathway with age-speciﬁc probabilities of progressing through the Lynch syndrome (LS) screening pathway. †Probability of meeting
inclusion criteria in the age-restricted scenarios is based on the age distribution of colorectal cancer (CRC) incidence data from 2008 to 2012.8 ‡MMR
deﬁciency is determined by testing with IHC and is deﬁned as loss of MMR expression in one or more of the four MMR genes (MLH1, PMS2, MSH2,
and MSH6). §Progression through the pathway is based on probabilities derived from Buchanan et al.18 These probabilities differ slightly as we consid-
ered LS cases that did not show MMR deﬁciency with IHC to be missed cases (three cases in screening < 60 and screening < 70 and four cases in
universal). In addition, one LS case was excluded from the probabilities in our analysis because although the case showed PMS2 loss, genetic testing
identiﬁed an MLH1 mutation, and this could not be factored into the model. Using screening < 50 as the example, 7.6% of all CRC cases were eligible
for testing with IHC to determine MMR deﬁciency status and 13.5% were MMR deﬁcient. Of these, 52.8% had loss of MLH1/PMS2, 18.1% had loss
of MSH2/MSH6, 12.5% had loss of MSH6 only, and 16.7% had loss of PMS2 only. Of the tumors with of MHL1/PMS2, 97.4% were BRAF wild type
and went on for germline testing. LS was conﬁrmed in 37.8% of CRC cases demonstrating MLH1/PMS2 loss, 61.5% of the cases demonstrating
MSH2/MSH6 loss, 77.8% of the cases demonstrating MSH6 loss, and 66.7% of the cases demonstrating PMS2 only. CRC, colorectal cancer; IHC,
immunohistochemistry; LS, Lynch syndrome; MMR, mismatch repair; < 60, age-speciﬁc probabilities for CRC cases aged under 60 years; 60–69,
age-speciﬁc probabilities for CRC cases aged between 60 and 69 years; 70+, age-speciﬁc probabilities for CRC cases aged over 70 years.
Costs and outcomes of Lynch syndrome DR Cenin et al.
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Sensitivity analyses. When the probability of a diagnosis of
LS was altered, our results changed signiﬁcantly (Table S1). Al-
though overall costs remained similar to the original analysis, in
the lower bound analysis, the number of LS cases diagnosed re-
duced to between 3.2 and 3.8, while the cost per LS case diag-
nosed increased ranged from $11 521 to $79 091. The reverse
was true for the upper bound analysis where the number of LS
cases diagnosed increased to between 7.0 and 23.7 and cost per
case detected ranged from $5350 to $13 731. A similar pattern
was seen when the age-speciﬁc probabilities derived from Hampel
et al.23 were applied to the MLH1-Pathway. Using these data, the
number of LS cases diagnosed in each age restricted scenario was
higher, and the cost per LS case diagnosed was lower. However,
program costs remained similar to our original analysis (Table S2).
Lowering adherence to genetic counseling and germline testing
reduced diagnostic yield by up to 25%. This resulted in a slight re-
duction in total costs (5–15% for MLH1-Pathway and 7–15% for
BRAF-Pathway), while the cost per LS case detected increased
(8–24% for MLH1-Pathway and 8–21% for BRAF-Pathway)
(Table S3). Similar results were found when both costs and accep-
tance of genetic counseling and germline testing were altered.
Changes to the cost parameters affected the costs proportionally
(Table 2 and tables in the Supporting Information).
Discussion
We developed a decision analysis model and used empirical data18
to determine the cost and yield of screening for LS per 1000 CRC
cases. Based on our results, screening for LS using the MLH1-
Pathway is more cost-effective than the BRAF-Pathway. Limiting
screening to CRC cases aged under 50 years in the MLH1-
Pathway would identify 5.2 LS cases per 1000 CRC cases for
the overall lowest cost, with a cost per LS case detected of
$7041. Expanding this pathway to also screen individuals aged
50–59 years (screening < 60) increased diagnostic yield by 28%
(1.5 cases). This was associated with a doubling of program costs,
an increase in cost per LS case detected (to $10 999) and an incre-
mental cost of $25 177 to detect one additional case. Screening
< 70 further increased diagnostic yield of screening with program
costs increasing by 88%. Cost per case detected in this scenario in-
creased to $16 685, equating to an incremental cost per additional
case detected of $40 278. Universal screening more than doubled
program costs compared with screening < 70 for no additional
yield; however, this was because no LS cases were identiﬁed in
this age group in our dataset. Cost per LS case detected increased
to $35 784. The BRAF-Pathway identiﬁed the same number of LS
cases; however, costs were higher for all age-at-diagnosis
thresholds.
There remains ongoing discussion about the optimal age to stop
screening for LS in the CRC-affected population,4,21 and our
model, like others,24–27 demonstrates that applying age restrictions
to screening criteria results in fewer LS cases being identiﬁed. This
impacts patient care and has downstream effects for at-risk rela-
tives who would not be identiﬁed, thereby diminishing the oppor-
tunity to commence interventions to reduce mortality and
morbidity in this cohort. However, concerns have been raised
about the feasibility of expanded screening for LS, particularly in
relation to the associated costs.24 While individuals with LS are
at higher risk of LS-related cancers compared with the general
population, the likelihood of developing such a cancer diminishes
with age.14 This suggests that, while expanding screening to in-
clude older individuals will identify more cases, the increased
Table 1 Cost parameters
Parameter Cost Source Range ($A)
Molecular tests
Mismatch repair immunohistochemistry 175 Expert opinion, Dr Tony Badrick, RCPAQAP (e-mail) 88–350†
MLH1 methylation testing 314 Expert opinion, Dr Benhur Amanuel, PathWest
Laboratory Medicine (e-mail)
157–628†
BRAF V600E testing 231 MBS Online22 115–462†
Combined diagnostic genetic test MLH1, MSH2, and MSH6‡ 1400 Expert opinion, Dr Karen Carpenter, PathWest
Diagnostic Genomics (e-mail)
700–2800†
Diagnostic genetic test PMS2§ 1000 500–2000†
Genetic counseling¶
Initial session 267†† Expert opinion, Anne Hawkins and Cassandra Nichols,
Genetic Services of Western Australia (e-mail)
92–455‡‡
LS diagnosis 251†† 78–438‡‡
LS inconclusive 22†† 7–36‡‡
All costs are presented in 2016 Australian dollars.
†Extrapolated range based on 50% reduction and a twofold increase.
‡Based on Illumina TruSight Cancer MPS panel (San Diego, California, USA) and two MLPA kits (MRC-Holland, Amsterdam, The Netherlands) for
MLH1, MSH2, and MSH6.
§Based on long-range PCR followed by Sanger sequencing and MLPA for PMS2.
¶Costs for genetic counseling vary according to the complexity of the counseling provided. To calculate the cost of the genetic counseling, we ﬁrst
established a range of costs using the shortest and longest duration of genetic counseling and the least to most complex counseling scenarios. The
average of these values was used in the analysis. Costs are divided into initial cost for genetic counseling, which includes planning and preparation
for individual consultations, and follow-up costs, which vary depending on the outcome of the genetic test.
††Mean cost of providing each service.
‡‡Range based on minimum duration and complexity to maximum duration and complexity of counseling service.
LS, Lynch syndrome; MLPA, Multiple Ligation-dependent Probe Ampliﬁcation; MPS, Massive Parallel Sequencing; PCR, polymerase chain reaction;
RCPAQAP, Royal College of Pathologists of Australasia Quality Assurance Program.
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detection will likely come at the expense of efﬁciency. In our
model, the proportion of CRC cases who demonstrate MMR pro-
tein loss by IHC and are subsequently found to be LS positive was
highest in the screening < 50 scenario (52% for both pathways).
This congruency reduced in the expanded alternatives (ranging
from 0% to 16%), demonstrating that although screening older in-
dividuals may detect additional LS cases, it does so by conducting
disproportionately greater numbers of tests which results in higher
program costs. This increase in overall cost could be considerable,
with our model demonstrating that universal screening cost was
more than twice as much as screening < 70 with no additional
beneﬁt in LS carrier detection.
Based on our results, there is added beneﬁt in ensuring CRC
cases < 70 years are screened and although this requires an in-
crease in total program cost, such an expansion could be consid-
ered a reasonable trade-off between costs and yield.25,27 While
our model suggests there is no additional beneﬁt of universal
screening compared with screening < 70, this is due to the lack
of LS cases identiﬁed in this age cohort in our study population.
As other investigations have conﬁrmed the existence of CRC-
affected LS mutation carriers in this age group,19,28 we conducted
a sensitivity analysis where we assessed the impact of adjusting
the proportion of individuals who were MMR deﬁcient but were
not conﬁrmed with LS (Table S1). In the case of universal screen-
ing, increasing this proportion of individuals diagnosed with LS
dramatically reduced the cost per LS case diagnosed (to between
$14 000 and $15 000) and the cost per additional LS diagnosis (ap-
proximately $25 000). In a second analysis, we applied the age-
speciﬁc probabilities of a US study evaluating the MLH1-
Pathway.30 Using these probabilities, we found similar overall
program costs for universal screening with a cost per additional
LS case detected of approximately $50 000 (Table S2). These re-
sults indicate that while there is potential beneﬁt in screening
CRC cases ≥ 70 years in terms of yield, cost-effectiveness of such
an expansion will be signiﬁcantly impacted by the proportion of
LS cases in this age cohort. Further studies with larger samples
are needed to enable more precise estimates.
Although screening for LS has shown to be cost-effective, con-
sensus of the optimal strategy is yet to be achieved. To our knowl-
edge, few studies have presented results based on age-restricted
inclusion criteria for the two pathways we investigated. One anal-
ysis investigating the BRAF-Pathway to screen for LS found it was
cost-effective to screen for LS in those aged < 70 years.27 A sec-
ond study found using MSI, in conjunction with IHC, to be cost-
effective across different age restrictions.25 However, when we in-
vestigated MSI in our preliminary analyses, we found its inclusion
was more costly than the alternative strategies for all age cohorts
with limited beneﬁt (results not shown). Analyses of universal
screening using the MLH1-Pathway have indicated that while this
strategy is cost-effective, it was not as cost-effective as possible al-
ternatives, with one study determining it was more cost-effective
to include both MLH1 methylation and BRAF V600E testing after
IHC,29 and the other ﬁnding cost-effectiveness improved when
CRC cases were ﬁrst triaged with the revised Bethesda guide-
lines.30 We have previously noted that implementation of clinical
guidelines in routine practice is poor,4,16,17 this would likely im-
pact the effectiveness of this strategy, leading to missed opportuni-
ties to diagnose LS and reduced cost-effectiveness. While
universal screening using BRAF-Pathway has also been shown toTa
bl
e
2
Y
ie
ld
an
d
co
st
s
fo
r
ea
ch
pa
th
w
ay
an
d
ag
e
re
st
ric
te
d
sc
en
ar
io
pe
r
10
00
in
di
vi
du
al
s
di
ag
no
se
d
w
ith
co
lo
re
ct
al
ca
nc
er
N
um
be
r
of
C
R
C
ca
se
s
un
de
rg
oi
ng
IH
C
te
st
in
g†
§
N
um
be
r
of
M
M
R
-
de
ﬁ
ci
en
t
ca
se
s
de
te
ct
ed
by
IH
C
‡
§
N
um
be
r
of
M
M
R
-
de
ﬁ
ci
en
t
ca
se
s
di
ag
no
se
d
as
LS
§
M
LH
1-
P
at
hw
ay
B
R
A
F-
P
at
hw
ay
To
ta
lc
os
t
of
LS
sc
re
en
in
g
C
os
t
pe
r
LS
di
ag
no
si
s
To
ta
lc
os
t
of
LS
sc
re
en
in
g
C
os
t
pe
r
LS
di
ag
no
si
s
P
oi
nt
es
tim
at
e§
Lo
w
er
bo
un
d
U
pp
er
bo
un
d
P
oi
nt
es
tim
at
e
Lo
w
er
bo
un
d
U
pp
er
bo
un
d
P
er
ad
di
tio
na
lL
S
ca
se
di
ag
no
se
d
P
oi
nt
es
tim
at
e§
Lo
w
er
bo
un
d
U
pp
er
bo
un
d
P
oi
nt
es
tim
at
e
Lo
w
er
bo
un
d
U
pp
er
bo
un
d
P
er
ad
di
tio
na
l
LS
ca
se
di
ag
no
se
d
S
cr
ee
ni
ng
<
50
76
10
5.
2
36
86
4
17
72
6
72
44
1
70
41
33
86
13
83
7
70
41
37
17
7
17
86
9
73
04
2
71
01
34
13
13
95
2
71
01
S
cr
ee
ni
ng
<
60
21
8
(+
14
2)
19 (+
9)
6.
7
(+
1.
5)
73
65
7
(+
36
79
4)
35
82
3
14
5
48
2
10
99
9
53
49
21
72
4
25
17
7
77
41
4
(+
40
23
7)
37
61
3
15
2
83
4
11
56
0
56
17
22
82
2
27
53
3
S
cr
ee
ni
ng
<
70
47
3
(+
25
5)
41 (+
22
)
8.
3
(+
1.
6)
13
8
66
3
(+
65
00
6)
67
89
3
27
4
70
3
16
68
5
81
69
33
05
4
40
27
8
14
7
52
0
(+
70
10
6)
72
11
0
29
2
03
2
17
75
1
86
77
35
14
0
43
43
8
U
ni
ve
rs
al
10
00
(+
52
7)
13
4
(+
93
)
8.
3
(+
0)
29
7
38
7
(+
15
8
72
4)
14
6
44
4
59
0
67
3
35
78
4
17
62
1
71
07
4
—
34
9
67
4
(+
20
2
15
4)
17
1
41
8
69
3
11
5
42
07
6
20
62
6
83
40
1
—
A
ll
co
st
s
ar
e
pr
es
en
te
d
in
20
16
A
us
tr
al
ia
n
do
lla
rs
.
†
N
um
be
r
of
ca
se
s
un
de
rg
oi
ng
IH
C
te
st
in
g
is
de
te
rm
in
ed
by
ag
e
at
C
R
C
di
ag
no
si
s.
P
ro
ba
bi
lit
y
of
m
ee
tin
g
in
cl
us
io
n
cr
ite
ria
in
th
e
ag
e
re
st
ric
te
d
sc
en
ar
io
s
is
ba
se
d
on
th
e
ag
e
di
st
rib
ut
io
n
of
C
R
C
in
ci
de
nc
e
da
ta
fr
om
20
08
to
20
12
.8
‡
N
um
be
r
of
M
M
R
ca
se
s
de
te
ct
ed
is
a
su
bs
et
of
th
e
nu
m
be
r
un
de
rg
oi
ng
IH
C
te
st
in
g
§
Fi
gu
re
s
in
pa
re
nt
he
se
s
re
pr
es
en
t
in
cr
ea
se
fr
om
pr
ev
io
us
sc
re
en
in
g
sc
en
ar
io
C
R
C
,c
ol
or
ec
ta
lc
an
ce
r;
IH
C
,i
m
m
un
oh
is
to
ch
em
is
tr
y;
LS
,L
yn
ch
sy
nd
ro
m
e;
M
M
R
,m
is
m
at
ch
re
pa
ir.
Costs and outcomes of Lynch syndrome DR Cenin et al.
1742 Journal of Gastroenterology and Hepatology 33 (2018) 1737–1744
© 2018 The Authors Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology
and Hepatology Foundation and John Wiley & Sons Australia, Ltd
be cost-effective,26,27,29,31 two studies indicated that this strategy
was not as effective as alternative strategies that included predic-
tive modeling as a ﬁrst step26 and the inclusion of both BRAF
V600E and MLH1 methylation testing.29 When we assessed the
BRAF-Pathway, we found it to be as effective but more expensive
than the MLH1-Pathway at all age thresholds. This was due to the
increased number of individuals undergoing germline testing in
the BRAF-Pathway as BRAF V600E only achieves ~75% efﬁ-
ciency as a surrogate marker for MLH1-methylated sporadic
CRC showing loss of MLH1/PMS2.18 Only one other study has
made a direct comparison between the two pathways we investi-
gated, and although the authors determined that the BRAF-
Pathway was more cost-effective than theMLH1-Pathway, the dif-
ferences were small.29
Beneﬁts of an LS screening program are dependent on ensuring
all eligible CRC cases are screened and that those detected with
MMR-deﬁciency receive genetic counseling and germline testing.
In our analysis, we assumed all eligible cases would undergo ap-
propriate testing; however, we recognize that this may not occur
in practice,17,32 as individuals may not wish to participate in ge-
netic testing because of, among other things, possible negative
psychological impacts (such as anxiety and depression) and con-
cerns over personal information.33 Reducing the proportion of
MMR-deﬁcient individuals who agree to genetic counseling and
subsequently agree to germline testing decreases yield and total
cost in all scenarios, while increasing cost per additional LS case
detected. Importantly, such reductions lead to more undiagnosed
cases of LS and missed opportunities to identify and monitor at-
risk relatives. The greatest beneﬁts of LS screening will only be
achieved if screening is appropriately implemented and eligible
cases have appropriate and informed access to genetic counseling
and germline testing.
An important strength of this study is that the model parameters
are derived from two large population-based studies for LS testing
and our results align with previous estimates of LS in the CRC
population.19,34 However, despite this, three limitations are of
note. Firstly, this analysis only examined testing incident CRC
cases with IHC. However, while we acknowledge that MSI test-
ing, either with or without IHC, is an alternative pathway for
triaging CRC cases,16,23 our preliminary analyses indicated that
this pathway was substantially more expensive, and therefore,
we excluded it from further investigations.
Secondly, this analysis only considers costs to identify LS in
CRC cases and does not take into account the subsequent costs
and cost savings of cascade screening and surveillance of at-risk
relatives. While predictive genetic testing of at-risk relatives has
been shown to be cost saving in Australia,35 there is currently no
research into the cost-effectiveness of surveillance in LS carriers.
Research with similar cost per LS case detected to ours, which also
assessed costs and beneﬁts of surveillance in this group found
screening for LS in those aged < 50 gained 43.6 life year
($7938/LYG).25 When screening was expanded to include those
aged 51–60 years, a further 118 life years were gained ($6380
per additional LYG). An additional 44.3 life years were gained
when those aged 61–70 years were screened ($10 648 per addi-
tional LYG). This suggests that with our cost per case detected,
cascade screening and surveillance of at-risk individuals will be
cost-effective at a willingness-to-pay threshold of $50 000. As
much of the beneﬁt in identifying LS relates to gains in life
expectancy in this group,36 future research should incorporate
analyses of these implications and costs.
Finally, data around the costs of laboratory testing for LS have
been difﬁcult to obtain, and our costs may not necessarily reﬂect
the range of costs throughout Australia. To account for this, we
conducted sensitivity analyses to provide the lower and upper cost
estimates.
Conclusions
Based on our analysis, MLH1 methylation testing as a follow-up
for CRCs showing loss of MLH1 protein expression is more
cost-effective than BRAF V600E somatic mutation testing in iden-
tifying LS cases. An expanded screening program that includes
screening CRC cases diagnosed <70 years will identify more LS
cases at a reasonable cost. Future research into the yield of LS
screening in CRC patients ≥ 70 years and the potential to offset ad-
ditional costs by identifying at-risk relatives is needed to determine
if universal screening is justiﬁed.
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